CA1058074A - Feline rhinotracheitis vaccine and production thereof - Google Patents
Feline rhinotracheitis vaccine and production thereofInfo
- Publication number
- CA1058074A CA1058074A CA221,970A CA221970A CA1058074A CA 1058074 A CA1058074 A CA 1058074A CA 221970 A CA221970 A CA 221970A CA 1058074 A CA1058074 A CA 1058074A
- Authority
- CA
- Canada
- Prior art keywords
- virus
- feline
- vaccine
- cats
- attenuated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 241000282324 Felis Species 0.000 title claims abstract description 58
- 229960005486 vaccine Drugs 0.000 title claims abstract description 55
- 206010051497 Rhinotracheitis Diseases 0.000 title claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 6
- 241000700605 Viruses Species 0.000 claims abstract description 106
- 241000282326 Felis catus Species 0.000 claims abstract description 83
- 230000003612 virological effect Effects 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims description 38
- 208000015181 infectious disease Diseases 0.000 claims description 21
- 239000012530 fluid Substances 0.000 claims description 20
- 230000002238 attenuated effect Effects 0.000 claims description 18
- 230000002458 infectious effect Effects 0.000 claims description 15
- 208000024891 symptom Diseases 0.000 claims description 14
- 239000002609 medium Substances 0.000 claims description 13
- 238000011534 incubation Methods 0.000 claims description 10
- 235000015097 nutrients Nutrition 0.000 claims description 10
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 claims description 8
- 239000002054 inoculum Substances 0.000 claims description 7
- 231100000252 nontoxic Toxicity 0.000 claims description 7
- 230000003000 nontoxic effect Effects 0.000 claims description 7
- 230000001902 propagating effect Effects 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 5
- 230000003053 immunization Effects 0.000 claims description 5
- 238000003306 harvesting Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 230000001681 protective effect Effects 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 abstract description 3
- 230000004048 modification Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 18
- 230000000120 cytopathologic effect Effects 0.000 description 12
- 238000011081 inoculation Methods 0.000 description 11
- 238000002255 vaccination Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000005875 antibody response Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 5
- 239000003104 tissue culture media Substances 0.000 description 5
- 210000001331 nose Anatomy 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000004407 Lactalbumin Human genes 0.000 description 3
- 108090000942 Lactalbumin Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- 210000005084 renal tissue Anatomy 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229930183010 Amphotericin Natural products 0.000 description 2
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 2
- 235000017276 Salvia Nutrition 0.000 description 2
- 241001072909 Salvia Species 0.000 description 2
- 206010044302 Tracheitis Diseases 0.000 description 2
- 229940009444 amphotericin Drugs 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004594 Masterbatch (MB) Substances 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010042618 Surgical procedure repeated Diseases 0.000 description 1
- 101150046432 Tril gene Proteins 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- -1 amine lactose glutamate Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 210000005257 cortical tissue Anatomy 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000009021 pre-vaccination Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/265—Infectious rhinotracheitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45434574A | 1974-03-25 | 1974-03-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1058074A true CA1058074A (en) | 1979-07-10 |
Family
ID=23804244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA221,970A Expired CA1058074A (en) | 1974-03-25 | 1975-03-13 | Feline rhinotracheitis vaccine and production thereof |
Country Status (12)
| Country | Link |
|---|---|
| JP (1) | JPS50154415A (cs) |
| AT (1) | AT340583B (cs) |
| AU (1) | AU502636B2 (cs) |
| BE (1) | BE827157A (cs) |
| CA (1) | CA1058074A (cs) |
| CH (1) | CH618091A5 (cs) |
| DE (1) | DE2512903A1 (cs) |
| ES (1) | ES436028A1 (cs) |
| FR (1) | FR2265405B1 (cs) |
| GB (1) | GB1462545A (cs) |
| NL (1) | NL7503499A (cs) |
| ZA (1) | ZA751854B (cs) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4287178A (en) * | 1974-03-25 | 1981-09-01 | Pitman-Moore, Inc. | Feline rhinotracheitis vaccine and production and use thereof |
| DE2544510A1 (de) * | 1975-10-04 | 1977-04-14 | Philips Nv | Virales rhinotracheitisvakzin fuer das katzengeschlecht und verfahren zu dessen herstellung |
| FR2327799A1 (fr) * | 1975-10-17 | 1977-05-13 | Philips Nv | Vaccin contre la rhinotracheite virale des felides et procede pour le preparer |
| US4031204A (en) * | 1976-03-30 | 1977-06-21 | Norden Laboratories, Inc. | Feline viral rhinotracheitis vaccine and combination feline viral rhinotracheitis-calicivirus vaccine prepared therefrom |
| US4303644A (en) * | 1979-10-16 | 1981-12-01 | Norden Laboratories, Inc. | Feline infectious peritonitis virus vaccines |
| JPS60196187A (ja) * | 1984-03-16 | 1985-10-04 | Biseibutsu Kagaku Kenkyusho:Kk | 牛のｒｓウイルス弱毒株 |
-
1975
- 1975-03-13 CA CA221,970A patent/CA1058074A/en not_active Expired
- 1975-03-21 AT AT219075A patent/AT340583B/de active
- 1975-03-24 ZA ZA00751854A patent/ZA751854B/xx unknown
- 1975-03-24 NL NL7503499A patent/NL7503499A/xx not_active Application Discontinuation
- 1975-03-24 JP JP50034594A patent/JPS50154415A/ja active Pending
- 1975-03-24 DE DE19752512903 patent/DE2512903A1/de not_active Withdrawn
- 1975-03-24 GB GB1220775A patent/GB1462545A/en not_active Expired
- 1975-03-24 AU AU79446/75A patent/AU502636B2/en not_active Expired
- 1975-03-24 FR FR7509162A patent/FR2265405B1/fr not_active Expired
- 1975-03-25 CH CH380275A patent/CH618091A5/de not_active IP Right Cessation
- 1975-03-25 ES ES436028A patent/ES436028A1/es not_active Expired
- 1975-03-25 BE BE154744A patent/BE827157A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES436028A1 (es) | 1978-06-01 |
| FR2265405A1 (cs) | 1975-10-24 |
| DE2512903A1 (de) | 1975-10-02 |
| JPS50154415A (cs) | 1975-12-12 |
| CH618091A5 (en) | 1980-07-15 |
| GB1462545A (en) | 1977-01-26 |
| BE827157A (fr) | 1975-09-25 |
| AU502636B2 (en) | 1979-08-02 |
| NL7503499A (nl) | 1975-09-29 |
| AU7944675A (en) | 1976-09-30 |
| FR2265405B1 (cs) | 1978-07-28 |
| AT340583B (de) | 1977-12-27 |
| ZA751854B (en) | 1976-10-27 |
| ATA219075A (de) | 1977-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU703084B2 (en) | Low pathogenicity prrs live virus vaccines and methods of preparation thereof | |
| US3950512A (en) | Animal vaccines | |
| US6086892A (en) | Poultry vaccine | |
| US3937812A (en) | Feline calicivirus vaccine and production thereof | |
| US3944469A (en) | Feline calicivirus vaccine and production thereof | |
| US4132775A (en) | Infectious bovine rhinotracheitis virus vaccine and method of preparing and using the same | |
| Benton et al. | The clinical and serological response of chickens to certain laryngotracheitis viruses | |
| US7462479B2 (en) | Infectious bronchitis virus vaccine | |
| CA1058074A (en) | Feline rhinotracheitis vaccine and production thereof | |
| Vindevogel et al. | Panzootic Newcastle disease virus in pigeons | |
| DE2323847C3 (de) | Lebendimpfstoff zur Immunisierung von Rindern gegen die Parainfluenza-3-Virus-Infektion | |
| US3907986A (en) | Live attenuated infectious bovine rhinotracheitis virus vaccines and preparation thereof | |
| US4225583A (en) | Intra-respiratory vaccine for prevention of Bordetella bronchiseptica infection and method of use | |
| US4287178A (en) | Feline rhinotracheitis vaccine and production and use thereof | |
| EP0600723B1 (en) | Infectious bursal disease vaccine | |
| FI94488C (fi) | Menetelmä rokotteen, joka suojaa kissoja kissojen tarttuvalta peritoniitilta, valmistamiseksi | |
| Castrucci et al. | Neonatal calf diarrhea induced by rotavirus | |
| Platt et al. | Pseudorabies: Experimental studies in raccoons with different virus strains | |
| Lumeij et al. | Paramyxovirus disease in racing pigeons: Clinical aspects and immunization. A report from the Netherlands | |
| JPS6222727A (ja) | 感染性気管支炎ワクチン | |
| SU1708839A1 (ru) | Штамм вируса инфекционного бронхита кур дл приготовлени вакцинных препаратов | |
| US5667785A (en) | Vaccine for protection of cats against feline infectious peritonitis | |
| TANENO et al. | Safety and efficacy of the cell-associated vaccine prepared by an attenuated infectious laryngotracheitis virus | |
| Beaudette | Infectious bronchitis and Newcastle disease | |
| Coria | Avian Infectious Bronchitis Virus: Serologic Response of Chickens to Seven Beta-Propiolactione-Inactivated Strains |